Arrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Reiterated by Piper Sandler
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “overweight” rating reaffirmed by stock analysts at Piper Sandler in a research report issued on Tuesday, Benzinga reports. They currently have a $62.00 price target on the biotechnology company’s stock. Piper Sandler’s price target points to a potential upside of 247.53% from the stock’s current […]
10 Oct 08:47 · The Markets Daily